Association of intermuscular and intramuscular fat with insulin resistance, type 2 diabetes, and metabolic syndrome: A systematic review.

Clin NutrJul 15, 2026 (epub)
Clinical ResearchEndocrinologyInternal Medicine (General)

Konstantinos Prokopidis, Gustavo Duque

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the relationship between intermuscular and intramuscular fat and cardiometabolic risks, including insulin resistance, type 2 diabetes, and metabolic syndrome in adults. The review included 17 studies with a total of 2945-8081 participants. Intermuscular fat was significantly associated with HOMA-IR (OR 2.72-2.67) and type 2 diabetes (OR 1.22-3.27).

Key findings

  • Intermuscular fat was associated with HOMA-IR (OR 2.72-2.67).
  • Intramuscular fat showed a strong link to HOMA-IR (OR 2.83).
  • Type 2 diabetes was associated with intermuscular fat (OR 1.22-3.27).
  • Muscle attenuation correlated with metabolic syndrome (OR 1.35-1.77), varying by sex.

Why it matters

Understanding the role of muscle fat in metabolic health is crucial for identifying individuals at risk for insulin resistance and related conditions. This knowledge can inform prevention strategies and interventions aimed at reducing cardiometabolic risk.

Source

PubMed · PMID 42485932

Published in Clin Nutr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.